Last reviewed · How we verify
NCT04672265
Increasing Access to Breast Cancer Screening Among Immigrants
NA trial testing Mother tongue and Norwegian in Cancer Screening in 11,355 participants. Participants enrolled and being followed up; not accepting new ones.
31 August 2022
Quick facts
| Lead sponsor | Oslo University Hospital |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | health services research |
| Enrollment | 11,355 |
| Start date | 15 April 2021 |
| Primary completion | 31 August 2022 |
| Estimated completion | 31 December 2030 |
| Sites | 1 location across Norway |
Drugs / interventions tested
- Mother tongue and Norwegian
Conditions studied
- Cancer Screening — all drugs for Cancer Screening →
Sponsor
Oslo University Hospital
Who can join
Adults 48 to 73, female only, with Cancer Screening. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators aim to test whether inviting immigrants to breast cancer screening with a letter in their mother tongue in addition to the standard letter in Norwegian changes screening uptake in these immigrant groups, compared with a comparable group who receive the invitation in Norwegian only,
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of invitation letter in language of origin on screening attendance: randomised controlled trial in BreastScreen Norway.
Hofvind S, Iqbal N, Thy JE, Mangerud G, et al · · 2023 · cited 9× · PMID 37726122 · DOI 10.1136/bmj-2023-075465
Verify or expand the search:
- PubMed search for NCT04672265
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer Screening
Currently open trials in the same condition.
- NCT06838689 — Participatory Approaches to Qualitative Research (PAQ): Comparing Two Approaches to Patient, Public and Clinician Involv · NA · recruiting
- NCT07087834 — Men's Perceptions, Attitudes, and Knowledge Levels Toward Cancer Screening · NA · active not recruiting
- NCT07075731 — Cervical and Endometrial Cancer Screening in Patients Seeking Gender-Affirming Hysterectomy · recruiting
- NCT07358715 — Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals · NA · recruiting
- NCT06371469 — Program of Health Behaviour Against to Cancer (PHeBAC) · NA · recruiting
Other Oslo University Hospital trials
Trials by the same sponsor.
- NCT07463885 — Spontaneous vs Controlled Mechanical Ventilation in Acute Hypoxemic Respiratory Failure · NA · not yet recruiting
- NCT07427719 — Retinopathy of Prematurity - Visual Function and Retinal Structure · not yet recruiting
- NCT07403331 — Severe Chronic Neuropathic Pain: A Treatment Bundle, Using Spinal Cord Stimulation and Multidisciplinary Treatment, to R · NA · recruiting
- NCT07449897 — Cholecystectomy With Intraoperative Management of Bile Duct Stones in Norway - the BILNOR Study · recruiting
- NCT06173817 — The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients · Phase 1 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04672265 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oslo University Hospital
- Last refreshed: 3 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04672265.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing